My oncology practice is running a celebrex + chemo trial for stage IIIs only. fOLFOX only, no avastin.
Trial Number: CALGB 80702
Trial Title: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
CALGB 80702 is a trial for patients with stage III colon cancer whose tumor has been completely resected. This trial has two main objectives. The first objective is to evaluate the benefit of adding 3 years of celecoxib to standard chemotherapy for colon cancer. Celecoxib is a non-steroidal anti-inflammatory drug that inhibits a family of enzymes, the COX family. The study is looking to determine whether the addition of celecoxib to chemotherapy reduces the risk of colon cancer recurrences. The standard chemotherapy for colon cancer is FOLFOX, which includes three drugs: 5-fluorouracil, leucovorin, and oxaliplatin. The second objective of the trial is to determine whether receiving FOLFOX chemotherapy for 6 treatments (12 weeks) is as good as 12 treatments (24 weeks) in preventing recurrence of colon cancer. Currently, the standard of care for stage III colon cancer is 12 treatments with FOLFOX. The trial also will look at whether the side effects of the chemotherapy treatment can be reduced with fewer treatments. Patients participating in this trial are randomized (a computer chooses) to one of four groups: 1. 12 cycles of FOLFOX plus Placebo daily for 3 years
2. 12 cycles of FOLFOX plus Celecoxib daily for 3 years
3. 6 cycles of FOLFOX plus Placebo daily for 3 years
4. 6 cycles of FOLFOX plus Celecoxib daily for 3 years
Eligibility Timeline: Patients are eligible to enroll 3 to 8 weeks after the resection of their tumor.
I looked this study up on the NCI database, and it says you take the celebrex with the Folfox - says nothing about continuing to take celebrex alone for three years. I'm confused. But anyway,
hmm.
Karin